

## NEONATAL Medication Monograph

## **HYDROXYCHLOROQUINE**

This document should be read in conjunction with this **DISCLAIMER** 

**Highly Restricted:** Requires Neonatologist or relevant specialist approval before commencing

Presentation	Oral Mixture: Hydroxychloroquine sulphate 200mg/5mL (KEMH/PCH)		
Description	Anti-malarial agent with anti-inflammatory activity		
Indications	<ul> <li>Juvenile rheumatoid arthritis (JRA)</li> <li>Systemic lupus erythematosus (SLE)</li> <li>May be used to treat chronic lung disease</li> </ul>		
Precautions	<ul> <li>Renal impairment</li> <li>Acute porphyrias</li> <li>Diabetes (may lower blood glucose)</li> <li>G6PD deficiency</li> <li>May aggravate myasthenia gravis, exacerbate psoriasis</li> <li>Neurological disorders (especially in those with a history of epilepsy)</li> <li>Severe gastrointestinal disorders</li> </ul>		
Dosage	Oral: 3 to 5mg/ kg/ day given as 1 or 2 divided doses		
Dosage Adjustment	Maximum: 7mg/kg/day		
Adverse Reactions	Common: gastrointestinal disturbances, skin reactions, bronchospasm, hypoglycaemia, muscle weakness  Serious: vision disturbances- changes to retina and cornea, bone marrow suppression, cardiomyopathy		
Interactions	Hydroxychloroquine may increase the levels/effects of beta blockers, cardiac glycosides, hypoglycaemia associated agents, QTc prolonging agents  The levels/effects of hydroxychloroquine may be decreased by quinolone antibiotics		

Preparation	Oral Solution Prepared in Pharmacy (KEMH/PCH)	
Administration	Oral: Give with or immediately after feeds	
Monitoring	Opthalmology examination at baseline and every 3 months with prolonged therapy	
	Full blood picture with differential and platelet count	
	Check for muscular weakness with prolonged therapy	
Storage	Store at room temperature, below 25°C	
Notes	Long term treatment with hydroxychloroquine is rarely associated with ocular toxicity; annual review of visual acuity is recommended.	
References	Takemoto CK, Hodding JH, Kraus DM. Pediatric & neonatal dosage handbook with international trade names index: a universal resource for clinicians treating pediatric and neonatal patients. 24th ed. Hudson (Ohio): Lexicomp; 2017. p. 1005	
	British National Formulary. BNF for Children. 2018-19 ed. London, UK: BMJ Group and Pharmaceutical Press; 2018. p.639	
	Kerem E, Bentur L, England S, Reisman J, O'Brodovich H, Bryan AC, Levison H. Sequential pulmonary function measurements during treatment of infantile chronic interstitial pneumonitis. The Journal of pediatrics. 1990 Jan 31;116(1):61-7.	
	Australian Medicines Handbook. Hydroxychloroquine. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2019 [cited 2020 Jan 17]. Available from: <a href="https://amhonline.amh.net.au/">https://amhonline.amh.net.au/</a>	
Related policies	WNHS Policy: Antimicrobial Stewardship	

Keywords	SLE, JRA, hydroxychloroquine, plaquenil				
Publishing:					
Document owner:	Head of Department - Neonatology				
Author / Reviewer:	KEMH & PCH Pharmacy / Neonatology Directorate				
Date first issued:	March 2008	Version:	3.0		
Last reviewed:	January 2020	Next review date:	January 2023		
Endorsed by:	Neonatal Directorate Management Group	Date:	January 2020		
Standards Applicable:	NSQHS Standards: 1 Governance, 3 Infection Control, 4 Medication Safety,				

Printed or personally saved electronic copies of this document are considered uncontrolled.

Access the current version from the WNHS website.

For any enquiries relating to this guideline, please email <a href="mailto:KEMH.PharmacyAdmin@health.wa.gov.au">KEMH.PharmacyAdmin@health.wa.gov.au</a>

© Department of Health Western Australia 2019